Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Methylnaltrexone Bromide
LINK HEALTHCARE SINGAPORE PTE LTD
A06AH01
12mg/0.6mL
INJECTION, SOLUTION
Methylnaltrexone Bromide 12mg/0.6mL
SUBCUTANEOUS
Prescription Only
DSM Pharmaceuticals, Inc
ACTIVE
2010-04-07
1. NAME OF THE MEDICINAL PRODUCT Relistor 12 mg /0.6 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.6 ml contains 12 mg methylnaltrexone bromide. One ml of solution contains 20 mg methylnaltrexone bromide. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Sterile, clear solution, colourless to pale-yellow, essentially free from visible particulates. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For adults only. RELISTOR should be added to induce prompt bowel movements when response to usual laxative therapy has been insufficient. The recommended dose of methylnaltrexone bromide is 8 mg (0.4 ml RELISTOR) (for patients weighing 38-61 kg) or 12 mg (0.6 ml RELISTOR) (for patients weighing 62-114 kg). The usual administration schedule is one single dose every other day. Doses may also be given with longer intervals, as per clinical need. Patients may receive two consecutive doses 24 hours apart, only when there has been no response (bowel movement) to the dose on the preceding day. Patients whose weight falls outside of the ranges should be dosed at 0.15 mg/kg. The injection volume for these patients should be calculated: Dose (ml) = patient weight (kg) x 0.0075 Renal patients No dose adjustment is required in patients with mild or moderate impairment. In patients with severe renal impairment (creatinine clearance less than 30 ml/min), reduce the dose Read the complete document
1. NAME OF THE MEDICINAL PRODUCT Relistor 12 mg /0.6 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.6 ml contains 12 mg methylnaltrexone bromide. One ml of solution contains 20 mg methylnaltrexone bromide. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Sterile, clear solution, colourless to pale-yellow, essentially free from visible particulates. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For adults only. RELISTOR should be added to induce prompt bowel movements when response to usual laxative therapy has been insufficient. The recommended dose of methylnaltrexone bromide is 8 mg (0.4 ml RELISTOR) (for patients weighing 38-61 kg) or 12 mg (0.6 ml RELISTOR) (for patients weighing 62-114 kg). The usual administration schedule is one single dose every other day. Doses may also be given with longer intervals, as per clinical need. Patients may receive two consecutive doses 24 hours apart, only when there has been no response (bowel movement) to the dose on the preceding day. Patients whose weight falls outside of the ranges should be dosed at 0.15 mg/kg. The injection volume for these patients should be calculated: Dose (ml) = patient weight (kg) x 0.0075 Renal patients No dose adjustment is required in patients with mild or moderate impairment. In patients with severe renal impairment (creatinine clearance less than 30 ml/min), reduce the dose of methylnaltrexone bromide by one half. There are no data available from patients with end-stage renal impairment on dialysis, and RELISTOR is not recommended in these patients (see section 4.4). Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2). There are no data available from patients with severe hepat Read the complete document